Proven as a diabetes drug. Slowing aging in people without diabetes still awaits a large trial.
Some reports say it blunts the benefits of exercise. For people who train, the math gets complicated.
Off-patent, so no one gets rich from it. What's at stake is the precedent of treating aging as an indication.